Previous 10 | Next 10 |
The American Association of Liver Diseases Annual Meeting, better known as The Liver Meeting, will open in Boston on Nov. 8. Data will be presented on new therapies for diseases ranging from hepatitis to non-alcoholic steatohepatitis (NASH), which affect hundreds of thousands, if not millions, o...
Thinly traded nano cap Hepion Pharmaceuticals (NASDAQ: HEPA ) is up 80% premarket on increased volume in reaction to preclinical data on NASH candidate CRV431. The data were just published in the Journal of Pharmacology and Experimental Therapeutics . More news on: Hepion ...
Nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty liver disease, is widely expected to be the next big thing in biopharma. Thanks to the out-of-control obesity pandemic and truckloads of research dollars pouring into this space at the moment, NASH drugs are projected to only...
Quick Take 89bio ( ETNB ) has filed to raise gross proceeds of $70 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on developing and commercializing treatments for liver and cardio-metabolic diseases. ETNB plans to start Phase 2 trials in 2020 a...
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has submitted a New Drug Appl...
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at...
It appears to be pretty clear that Intercept Pharmaceuticals (NASDAQ: ICPT) will beat Gilead Sciences (NASDAQ: GILD) in the race to launch the first drug for treating nonalcoholic steatohepatitis (NASH). Gilead's late-stage disappointments for selonsertib caused a big setback for the c...
New NASH survey available on NASHTRUTH.com reveals that 6 out of 10 NASH patients say there is not enough information about the disease available to them NASHTRUTH.com provides people living with NASH with resources to start a more productive dialogue with their healthcar...
Non-alcoholic steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease, is easily the world's largest untapped drug market. NASH drug sales, in fact, could exceed an eye-popping $62 billion as soon as 2028, according to various Wall Street analysts and industry inside...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...